ChromaDex has announced that European Member States have voted in favour of listing Nicotinamide Riboside Chloride (NR) as a novel food ingredient at a daily serving of 300mg for the healthy adult population.

The approval follows a positive opinion issued by the European Food Safety Authority (EFSA) in August 2019.

“We are pleased to be extending our global footprint into Europe,” said ChromaDex CEO Rob Fried. “We are committed to offering Tru Niagen to health-conscious people worldwide.”

“The decision by the European Commission is a meaningful occasion not only for ChromaDex but also for researchers around the world studying nicotinamide riboside,” said Professor Sir John Walker, Nobel Laureate and Emeritus Director, MRC Mitochondrial Biology Unit in the University of Cambridge, England, and member of the ChromaDex Scientific Advisory Board (SAB). “ChromaDex has been at the forefront of both clinical and preclinical research behind NR and NAD.”

Tru Niagen is described as a breakthrough supplement clinically proven to increase NAD (nicotinamide adenine dinucleotide) levels which stimulate cellular energy production and support cellular repair. Decreased NAD levels have been associated with many age-related declines in overall health. Nicotinamide riboside chloride (NR) has been the subject of rigorous preclinical safety and toxicology studies laying the groundwork for the published clinical studies that demonstrate safety and efficacy.

To date, ChromaDex has invested millions of dollars in safety and human clinical trials on its patent-protected NR (commercially known as Niagen) and has entered research agreements with more than 170 leading research institutions, including Dartmouth, the National Institutes of Health, University of Iowa, and the Scripps Research Institute.

Editors Note: